Decoy Therapeutics registers resale of 3.77M shares underlying June private placement warrants, unlocking a potential $19.1M cash inflow upon exercise

summarizeSummary

Decoy Therapeutics filed an S-1 to register the resale of 3.77 million shares underlying warrants from its June 29 private placement. The registration makes the overhang tradable and quantifies up to $19.1 million in potential future cash from warrant exercises, but also exposes the stock to massive dilution—outstanding shares could increase more than 8x if all warrants and preferred stock convert.

check_boxKey Events · Financing and Capital Events · DCOY

• Resale Registration for 3.77M Shares

  Registers resale of 3,766,500 shares underlying warrants from the June 29 private placement, making the overhang tradable. The shares represent over 7x the current outstanding share count of 531,968.

• Potential $19.1M Cash Inflow from Warrant Exercises

  If all warrants are exercised for cash, the company could receive up to $19.1 million: $59 from Pre-Funded Warrants (exercise price $0.0001), $17.5 million from Milestone Warrants ($5.91), and $1.6 million from Placement Agent Warrants ($7.3875). Milestone Warrants require stockholder approval and achievement of clinical milestones.

• Going Concern and Cash Runway Pressure

  The company has a going-concern warning and cash runway only into late 2026. The $3.5 million upfront from the private placement provides short-term relief, but the potential $19.1 million from warrant exercises is uncertain and contingent on milestones and stockholder approval.

• Single Investor Concentration and Selling Stockholders

  Armistice Capital Master Fund Ltd. holds 87% of the registered shares (3,553,302 shares). The remaining shares are held by the placement agent and its designees. Resales by these parties could significantly pressure the stock.

auto_awesomeAnalysis · DCOY · Life Sciences

This S-1 registers the resale of 3.77 million shares underlying warrants from the $3.5 million private placement that closed June 29. While the upfront raise was just $3.5 million, the registration makes the overhang tradable and quantifies a potential $19.1 million in additional cash if all warrants are exercised—a critical detail for a company with a going-concern warning and a cash runway that extends only into late 2026. The filing also reveals that a single institutional investor, Armistice Capital, holds 87% of the registered shares, and that the company faces liquidated damages of up to 10.5% of the investor's subscription if it misses SEC effectiveness deadlines. Against a backdrop of a $3.1 million market cap and a stock trading at $5.91, the potential dilution is enormous: outstanding shares could rise from 531,968 to over 4.3 million if all warrants and preferred stock convert. The registration itself doesn't sell shares, but it arms the selling stockholders to liquidate, creating a significant overhang that could pressure the stock.